Fig. 2

A Waterfall plot for the best percentage change of furmonertinib in CNS lesions in the cEFR. The dashed lines at 20% and -30% indicate the thresholds for PD and PR, respectively. One patient in 80 mg orally once daily group was not evaluable. B Forest plot of subgroup of patients having objective response of furmonertinib in the cEFR. The reference line at 65% represented the overall CNS-ORR. CNS, central nervous system. cEFR, CNS evaluable-for-response set. PD, progressive disease. PR, partial response. ORR, objective response rate. DCR, disease control rate. CI, confidence interval. EGFR, epidermal growth factor receptor